Medically reviewed by Doru Paul, MD Multiple myeloma is a type of blood cancer that develops in plasma cells, a type of white ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

The Department of Veterans Affairs has started the process to designate multiple myeloma and acute and chronic leukemias as linked to military service in the Persian Gulf, Afghanistan and ...

To open multiple folders at once on Windows 11/10 computer, there are two methods, and both of them share some differences. Open all the folders in separate windows Open one folder in the current ...

International Myeloma Foundation: “Multiple Myeloma and Anemia,” “Heart and Lung Complications.” Memorial Sloan Kettering Cancer Center: “Bone-Related Problems in Multiple Myeloma ...

Multiple myeloma is considered to be relapsed if symptoms of the disease appear after a time of improvement. It’s considered to be refractory when it gets worse even though it’s being treated.

This medication is a human monoclonal antibody, prescribed for osteoporosis, treatment induced bone loss, bone metastases, rheumatoid arthritis, multiple myeloma and giant cell tumor of bone.

Equecabtagene autoleucel showed high efficacy in relapsed/refractory multiple myeloma, with a 96% overall response rate and 42.6% complete response rate at three months. Minimal residual disease ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead Sciences' Kite Pharma to treat relapsed or refractory multiple myeloma (RRMM). After seeing the data ...

Treatment with an experimental CAR-T therapy for multiple myeloma from Arcellx and Gilead Sciences resulted in zero cases of delayed neurotoxicity, including Parkinsonian symptoms and cranial ...

The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J’s Carvykti, although Wall Street analysts were divided on how the two drugs compare. Carvykti ...